Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer
Rodríguez Barrueco, Ruth
Santacana Espasa, Maria
Gatius Calderó, Sònia
Martí, Maria Dolores
Bergadà Bertran, Laura
Llobet Navàs, David
MetadataShow full item record
Targeted therapies in endometrial cancer (EC) using kinase inhibitors rarely result in complete tumor remission and are frequently challenged by the appearance of refractory cell clones, eventually resulting in disease relapse. Dissecting adaptive mechanisms is of vital importance to circumvent clinical drug resistance and improve the efficacy of targeted agents in EC. Sorafenib is an FDA-approved multitarget tyrosine and serine/threonine kinase inhibitor currently used to treat hepatocellular carcinoma, advanced renal carcinoma and radioactive iodine-resistant thyroid carcinoma. Unfortunately, sorafenib showed very modest effects in a multi-institutional phase II trial in advanced uterine carcinoma patients. Here, by leveraging RNA-sequencing data from the Cancer Cell Line Encyclopedia and cell survival studies from compound-based high-throughput screenings we have identified the lysosomal pathway as a potential compartment involved in the resistance to sorafenib. By performing additional functional biology studies we have demonstrated that this resistance could be related to macroautophagy/autophagy. Specifically, our results indicate that sorafenib triggers a mechanistic MAPK/JNK-dependent early protective autophagic response in EC cells, providing an adaptive response to therapeutic stress. By generating in vivo subcutaneous EC cell line tumors, lung metastatic assays and primary EC orthoxenografts experiments, we demonstrate that targeting autophagy enhances sorafenib cytotoxicity and suppresses tumor growth and pulmonary metastasis progression. In conclusion, sorafenib induces the activation of a protective autophagic response in EC cells. These results provide insights into the unopposed resistance of advanced EC to sorafenib and highlight a new strategy for therapeutic intervention in recurrent EC.
Is part ofAutophagy, 2017, vol. 13, núm. 3, p. 1-17
European research projects
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as cc-by (c) Núria Eritja, et al. 2017
Showing items related by title, author, creator and subject.
KSR1 is overexpressed in endometrial carcinoma and regulates proliferation and TRAIL-induced apoptosis by modulating FLIP levels Llobet Navàs, David; Eritja Sánchez, Núria; Domingo, Mónica; Bergadà Bertran, Laura; Mirantes Barbeito, Cristina; Santacana Espasa, Maria; Pallares, Judit; Macià Armengol, Anna; Yeramian Hakim, Andree; Encinas Martín, Mario; Moreno-Bueno, Gema; Palacios, José; Lewis, Robert E.; Matias-Guiu, Xavier; Dolcet Roca, Xavier (Elsevier Inc, 2011)The Raf/MEK/extracellular signal-regulated kinase (ERK) pathway participates in many processes altered in development and progression of cancer in human beings such as proliferation, transformation, differentiation, and ...
A Smad3-PTEN regulatory loop controls proliferation and apoptotic responses to TGF-β in mouse endometrium Eritja Sánchez, Núria; Felip, Isidre; Dosil Garcia, Maria Alba; Vigezzi, Lucia; Mirantes Barbeito, Cristina; Yeramian Hakim, Andree; Navaridas Fernández de Bobadilla, Raúl; Santacana Espasa, Maria; Llobet Navàs, David; Yoshimura, Akihiko; Nomura, Masatoshi; Encinas Martín, Mario; Matias-Guiu, Xavier; Dolcet Roca, Xavier (Nature Publishing Group, 2017-05-19)The TGF-β/Smad and the PI3K/AKT signaling pathways are important regulators of proliferation and apoptosis, and their alterations lead to cancer development. TGF-β acts as a tumor suppressor in premalignant cells, but it ...
Combination of Vorinostat and caspase-8 inhibition exhibitshigh anti-tumoral activity on endometrial cancer cells Eritja Sánchez, Núria; Bergadà Bertran, Laura; Sorolla Bardají, Anabel; Yeramian Hakim, Andree; Mirantes, Cristina; Matias-Guiu, Xavier; Dolcet Roca, Xavier (Elsevier, 2013)Histone deacetylase inhibitors such as Vorinostat display anti-neoplastic activity against avariety of solid tumors. Here, we have investigated the anti-tumoral activity of Vorinostaton endometrial cancer cells. We have ...